Lantern Pharma is trading 5.9% down at $0.94 amid a recent offering; reporting has not confirmed it caused the October 2 move.
- The company closed a registered direct offering of 3,669,725 shares at $1.09, raising approximately $4 million before expenses, plus warrants for up to the same number of shares.
- The broader market is higher after weaker-than-expected September payroll growth; index-wide weakness does not explain the drop.
- Provided price history shows substantial losses in recent sessions.